The British Business Bank (BBB) has announced an investment of £ 8 million to NRG Theraputics Limited, a leading neuroscience company developing novel therapy for serious neurodynative conditions, developing novel therapy, which is as part of the £ 50 million series B funding round.
The financing was led by SV Health Investors Dementia Discovery Fund (DDF), with the involvement of M Ventures, Naurtis Venture Fund and Criteria Bio Ventures with existing backcards omega funds and Brandon Capital.
NRG theraputics are pursuing treatment by targeting mitochondrial dysfunction for amyotrophic lateral sclerosis (ALS)/Motor Neurone Disease (MND) and Parkinson's disease, which is a major driver of neurodizonation.
The company has developed a new class of small molecules mitochondrial permeability infection por (MPTP) inhibitors, designed to protect mitochondria from toxic proteins associated with ALS/MND and Parkinson's, and preserved neurons in pre-granical models.
Its prominent candidate, NRG5051, has shown intense neuroprottive effects and low neuroinphlection in pre-nervous studies. After completing the ind-enabling task, NRG5051 is expected to enter the first human clinical trials in early 2026.
Series B will enable NRG to generate clinical evidence of concept in ALS/MND by collecting meaningful data in Parkinson's patients.
NRG theraputics co-founder and CEO Dr. Neil Miller said Rise has intensified the company's mission to provide new hope for patients and families affected by destructive neurological diseases: “It is very challenging to develop new drugs for the treatment of neurological diseases, which is more challenging to increase new funds. To expand our portfolio to other signals including Parkinson's.”
The British Business Bank's Chief Investment Officer, Lyndros Kalispus, said that NRG underlined the bank's focus on scaling the UK Life Sciences Breakthrough: “We try to return the best of the UK Life Sciences, which help for success in the world-headed, fully professional companies.”
Senior investment manager Emma Johnson at the bank said: “We are pleased to join the NRG in this next phase of development as they carry forward their novel therapy with a disease-propelled ability in the clinic. It makes them a 16th life science direct investment for the British trade bank, which supplements our existing portfolio to our existing portfolio.”
In collaboration with Series B Rise, Emma Johnson (British Business Bank), Lawrence Barker (SV Health Investors), Charlotte Kramer (M Ventures) and Florian Muelarsen (Novartis Venture Fund) will join the board of directors of NRG, which will bring additional expertise as a company infection.
Amy Ingam
Amy is a newly eligible journalist who specializes in business journalism with expertise in professional journalism, now with the responsibility of news material for the biggest print of the UK and the online source of current business news.